Floatz logo

Azacitidine

Leukemia Cutis

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Leukemia Cutis cohort.

Asset / SponsorPhaseRating
ASPARAGINASE
National Cancer Institute (NCI)
Phase 3BB
Daunorubicin
National Cancer Institute (NCI)
Phase 3BB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 3BB
Cytosin-Arabinosid
National Cancer Institute (NCI)
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
National Cancer Institute (NCI)
Phase 3BB

View all 15 →

Same molecule, other indications

Azacitidine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
73 / 100
View asset →
acute erythroid leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
non-small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →